Jon Block

Jon Block of Stifel challenged the assertion that Zoetis's implied 3% organic operational growth exit in Q4 2025, despite an easier comparison, is not indicative of 2026 performance, questioning what changes in the price/volume algorithm would drive a rebound given anticipated zero-ish volume in 2H 2025 and increasing competition in key franchises like dermatology.

Answer

CFO Wetteny Joseph reiterated that the Q4 exit is not a read-through for 2026, citing expected stabilization and return to growth for Librela. He explained that competitive pressures, while aggressive, have resulted in limited patient share gains, and their impact is amplified by the current macro environment of fewer therapeutic visits. Joseph noted that international dermatology grew 7% despite aggressive competition due to market expansion, and historically, initial launch promotions are short-lived. He expressed confidence in Zoetis's strong portfolio and upcoming approvals.

Jon Block pressed on why the implied 3% organic operational growth in Q4 2025, despite an easier comparison, is not considered indicative for 2026. He asked what changes in the price/volume algorithm are expected, specifically if price will go higher or if volumes will rebound, and the rationale behind this outlook.

Answer

Wetteny Joseph, Chief Financial Officer, reiterated that the Q4 exit is not indicative of 2026, citing expected Librela stabilization and a return to growth. He acknowledged competitive pressure but emphasized Zoetis's strong market position in dermatology (11 years, 120 million doses of Apoquel/Cytopoint) and high customer satisfaction. Joseph noted that the macro environment (fewer therapeutic visits) amplifies competitive impact, but highlighted that international dermatology grew 7% despite aggressive competition due to market expansion. He stated that initial launch promotions are typically short-lived and Zoetis will maintain discipline.

Jon Block asked about the sustainability of OpEx leverage into 2026, questioning if it's a 'pure role reversal' due to the 15-day sensor or if additional OpEx opportunities exist, and whether 'catch-up spend' is anticipated.

Answer

Jereme Sylvain, CFO, stated that 2025 OpEx leverage resulted from efficiency improvements, not deferrals, so no significant 'catch-up spend' is anticipated. He expects continued gross margin improvement in 2026 and opportunities for further OpEx leverage, balancing investment for growth (especially with potential coverage expansions) with delivering operating margin improvement to shareholders.

Jon Block asked about OpEx leverage in 2025 offsetting gross margin shortfalls, and whether 2026 will see a 'pure role reversal' due to 15-Day, additional OpEx opportunities, or 'catch-up spend.'

Answer

Jereme Sylvain, CFO, stated that 2025 OpEx work focused on efficiency and leveraging existing investments, not deferrals or 'catch-up spend.' He expects gross margin opportunities in 2026 and continued OpEx leverage, balancing investment with delivering operating margin improvement, especially if coverage expands.

Jon Block of Stifel asked about the key performance indicators Nexeo will track for its GENEO system launch through the end of 2025, and inquired how the company plans to leverage its differentiated product label in its go-to-market strategy.

Answer

CFO John Landry stated that Nexeo is tracking leading indicators like the number of trained physicians and value analysis committee (VAC) applications, with more metrics to be shared on future calls. CEO Olivier Talman added that the differentiated label, particularly the data on positional OSA and the lack of a contraindication for complete concentric collapse (CCC), is a significant competitive advantage that will be used to persuade physicians to choose GENEO.

Joe Federico, on behalf of Jon Block, questioned the Q2 revenue result, which was below models, and asked if competitor supply issues in prior quarters had played a role. He also sought clarity on the expected timing of FDA approval (late 2024 vs. early 2025) and the planned size of the initial U.S. sales team.

Answer

CEO Olivier Taelman attributed the quarterly revenue variability to the small size of the German market, while noting year-over-year growth remains strong. He downplayed the impact of competitor shortages and expressed confidence in second-half growth, partly driven by the ResMed collaboration. Taelman reiterated confidence in a late 2024 FDA approval based on the 180-day review clock but added a prudent mention of early 2025. He confirmed the initial U.S. launch team would consist of 15 territory managers supported by 15 field engineers and specialists.